| 臺大學術典藏 |
2018-09-10T05:01:24Z |
Pharyngeal-brachial palsy after cytomegalovirus colitis
|
Pan, C.-L. and Shun, C.-T. and Susuki, K. and Yuki, N. and Hsieh, S.-T.; SUNG-TSANG HSIEH |
| 元智大學 |
2015-11-05 |
PHAs surface modification by plasma technology
|
Chih-Kai Chang; Chi-Wei (John) Lan; Hui-Min David Wang |
| 國家衛生研究院 |
2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors
|
Lin, CC;Chiang, NJ;Lee, JH;Chen, MH;Chao, Y;Su, WC;Bai, LY;Wu, SY;Hsu, CH;Shan, YS;Li, CP;Chen, SH;Chung, WP;Chen, LT |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Chia-Chi Lin; Akimov M; Ghebremariam S; Hong D; Poon R.T.P; Azaro A; Lim W.T; Bauer T.M; Nam D.-H; Schuler M; Su W.-C; Bang Y.-J; Zhao S; Giovannini M; Ma B. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; Chia-Chi Lin; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. |
| 國立成功大學 |
2020 |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang, Y.-J.;Su, W.-C.;Schuler, M.;Nam, D.-H.;Lim, W.T.;Bauer, T.M.;Azaro, Azaro A.;Poon, R.T.P.;Hong, D.;Lin, C.-C.;Akimov, M.;Ghebremariam, S.;Zhao, S.;Giovannini, M.;Ma, B. |
| 國家衛生研究院 |
2022-02 |
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors
|
Bai, LY;Chiang, NJ;Hsu, CH;Liang, YH;Chiu, CF;Lin, CC;Chang, KY;Chen, SH;Tsai, HJ;Lin, YP;Chen, LT;Lin, CC |
| 國立臺灣大學 |
2015 |
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
|
Venkatakrishnan, Karthik; Kim, Tae Min; Lin, Chia-Chi; Thye, Lim Soon; Chng, Wee Joo; Ma, Brigette; Chen, Ming Huang; Zhou, Xiaofei; Liu, Hua; Kelly, Virginia; Kim, Won Seog; 林家齊 |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose
|
Venkatakrishnan K; Kim T.M; Chia-Chi Lin; Thye L.S; Chng W.J; Ma B; Chen M.H; Zhou X; Liu H; Kelly V; Kim W.S. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 國家衛生研究院 |
2021-06-12 |
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
|
Chang, KY;Chiang, NJ;Wu, SY;Yen, CJ;Chen, SH;Yeh, YM;Li, CF;Feng, XX;Wu, K;Johnston, A;Bomalaski, JS;Wu, BW;Gao, JJ;Subudhi, SK;Kaseb, AO;Blando, JM;Yadav, SS;Szlosarek, PW;Chen, LT |
| 國立成功大學 |
2021 |
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
|
Chang, K.-Y.;Chiang, N.-J.;Wu, S.-Y.;Yen, C.-J.;Chen, S.-H.;Yeh, Yeh Y.-M.;Li, C.-F.;Feng, X.;Wu, K.;Johnston, A.;Bomalaski, J.S.;Wu, B.-W.;Gao, J.;Subudhi, Subudhi S.K.;Kaseb, A.O.;Blando, J.M.;Yadav, S.S.;Szlosarek, P.W.;Chen, L.-T. |
| 臺大學術典藏 |
2022-05-05T09:10:02Z |
Phase 1�V3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22
|
Oberguggenberger A.S.; Nagele E.; Inwald E.C.; Tomaszewski K.; Lanceley A.; Nordin A.; Creutzberg C.L.; Kuljanic K.; Kardamakis D.; Schmalz C.; Arraras J.; Costantini A.; Almont T.; Wei-Chu C.; Dehandschutter S.; Winters Z.; Greimel E.; the EORTC Quality of Life Group |
| 國立臺灣大學 |
2010 |
Phase 2 Results of Xl184 in a Cohort of Patients Pts with Advanced Non- Small Cell Lung Cancer Nsclc
|
楊志新; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2021-01-06T03:58:18Z |
Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation
|
Maertens J.; Logan A.C.; Jang J.; Long G.; JIH-LUH TANG; Hwang W.Y.K.; Koh L.P.; Chemaly R.; Gerbitz A.; Winkler J.; Yeh S.-P.; Hiemenz J.; Christoph S.; Lee D.-G.; Wang P.-N.; Holler E.; Mielke S.; Akard L.; Yeo A.; Ramachandra S.; Smith K.; Pertel P.; Segal F. |
| 臺北醫學大學 |
2014 |
Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma
|
Chen, Shang-Wen;Lin, Li-Ching;Kuo, Yu-Cheng;Liang, Ji-An;Kuo, Chia-Chun;Chiou, Jeng-Fong |
| 臺大學術典藏 |
2020-07-05T05:26:30Z |
Phase 2 Study of IV Vinorelbine in Relapsed Platinum Resistant/Refractory C5 High Grade Serous, Endometrioid or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
|
V Heong;J Ye;G Au Yeung;Tz Tan;D Bowtell;Ruby Yun-Ju Huang;M Linda;D Tan; V Heong; J Ye; G Au Yeung; TZ Tan; D Bowtell; RUBY YUN-JU HUANG; M Linda; D Tan |
| 臺大學術典藏 |
2021-01-12T12:49:04Z |
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
|
Cronier D.M.; Nguyen T.S.; Conti I.; Kaiser C.J.; Wooldridge J.E.; Tai D.F.; Kuliczkowski K.; Beksac M.; Raje N.S.; Moreau P.; Terpos E.; Benboubker L.; Grz??ko N.; Holstein S.A.; Oriol A.; SHANG-YI HUANG; Palumbo A. |
| 國立成功大學 |
2013-08-15 |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Kwak, Eunice L.; Shapiro, Geoffrey I.; Cohen, Seth M.; Becerra, Carlos R.; Lenz, Heinz-Josef; Cheng, Wen-Fang; Su, Wu-Chou; Robohn, Meghan; Le Maulf, Florence; Lobmeyer, Maximilian T.; Chand, Vikram K.; Iafrate, A. John |
| 臺大學術典藏 |
2020-02-06T05:22:03Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Iafrate A.J.;Chand V.K.;Lobmeyer M.T.;Le Maulf F.;Robohn M.;Su W.-C.;WEN-FANG CHENG;Lenz H.-J.;Becerra C.R.;Cohen S.M.;Shapiro G.I.;Kwak E.L.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 臺大學術典藏 |
2020-02-14T02:49:50Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 國立臺灣大學 |
2011 |
Phase 2 Trial of Linifanib (Abt-869) in Patients with Advanced Non-Small Cell Lung Cancer
|
楊志新; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
|
Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A.; Tan E.-H;Goss G.D;Salgia R;Besse B;Gandara D.R;Hanna N.H;Chih-Hsin Yang;Thertulien R;Wertheim M;Mazieres J;Hensing T;Lee C;Gupta N;Pradhan R;Qian J;Qin Q;Scappaticci F.A;Ricker J.L;Carlson D.M;Soo R.A.; Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG; Thertulien R; Wertheim M; Mazieres J |
| 臺大學術典藏 |
2021-07-03T03:34:18Z |
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
|
Toh H.C.; PEI-JER CHEN; Carr B.I.; Knox J.J.; Gill S.; Ansell P.; McKeegan E.M.; Dowell B.; Pedersen M.; Qin Q.; Qian J.; Scappaticci F.A.; Ricker J.L.; Carlson D.M.; Yong W.P. |
